Literature DB >> 11441425

Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers.

D J Walker1, J P Zacny, K E Galva, J L Lichtor.   

Abstract

RATIONALE: Conducting complete dose-response evaluations of multiple drugs in a single within-subjects experiment is very time-consuming when a complete session is required for evaluation of each dose.
OBJECTIVE: To evaluate a within-session cumulative-dosing procedure as a potentially efficient method for conducting dose-response evaluations of mixed-action opioids.
METHODS: Fifteen healthy volunteers received intravenous injections of saline, butorphanol, nalbuphine, pentazocine, or morphine in a randomized, double-blind, crossover design. Subjects received one injection per hour for the first 4 h, and a 3-h recovery period followed. Saline was injected first, then saline or increasing doses of each drug (except pentazocine, see below) were administered every hour for the next 3 h. The absolute doses per injection were morphine and nalbuphine 2.5, 5, and 10 mg/70 kg, butorphanol 0.5, 1, and 2 mg/70 kg, and pentazocine 7.5, 15, and 0 mg/70 kg. (The highest dose of pentazocine was omitted because of the risk of dysphoria and psychotomimesis). These injections resulted in cumulative doses of morphine or nalbuphine 2.5, 7.5, and 17.5 mg/70 kg, butorphanol 0.5, 1.5, and 3.5 mg/70 kg, and pentazocine 7.5 and 22.5 mg/70 kg. Mood, psychomotor performance, and vital signs were assessed.
RESULTS: Effects of all opioids were similar, with some exceptions. Butorphanol had the strongest effects on psychomotor performance and some subjective effects. Morphine was associated with delayed or prolonged side effects.
CONCLUSIONS: Orderly dose-response functions and replication of results of single-dosing studies confirmed that the cumulative-dosing procedure is an efficient way of determining dose-response functions for multiple opioids within the same subjects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441425     DOI: 10.1007/s002130100723

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

3.  Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

Authors:  Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; D Andrew Tompkins
Journal:  Anesthesiology       Date:  2019-01       Impact factor: 7.892

Review 4.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

5.  Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.

Authors:  Barth L Wilsey; Scott Fishman; Chin-Shang Li; Jeanna Storment; Anthony Albanese
Journal:  Pharmacol Biochem Behav       Date:  2009-08-04       Impact factor: 3.533

6.  Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers.

Authors:  Nathalie V Goletiani; Jack H Mendelson; Michelle B Sholar; Arthur J Siegel; Alicja Skupny; Nancy K Mello
Journal:  Pharmacol Biochem Behav       Date:  2007-02-20       Impact factor: 3.533

7.  The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Michelle R Lofwall; Joseph R Holtman
Journal:  Drug Alcohol Depend       Date:  2008-07-07       Impact factor: 4.492

8.  Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.

Authors:  Jermaine D Jones; Mudassir Mumtaz; Jeanne M Manubay; Shanthi Mogali; Elliana Sherwin; Suky Martinez; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2019-09-04       Impact factor: 3.533

9.  The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.

Authors:  Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Shanthi Mogali; Verena E Metz; Roberto Ciccocioppo; Sandra D Comer
Journal:  Physiol Behav       Date:  2015-10-09

10.  Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Authors:  Sarah L Withey; Carol A Paronis; Jack Bergman
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.